2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Thursday, March 30, 2023

6:00PM-7:00PM: Abstract Number: 063

JAK Inhibition in down Syndrome Associated Arthritis (DA) – Our Experience to Date with Tofacitinib in 5 Patients

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 051

Juvenile Relapsing Polychondritis: A Single Center Cohort

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 072

Musculoskeletal Ultrasound Findings in Children with Psoriasis

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 069

Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios of Patients with Juvenile Systemic Lupus Erythematosus

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 068

Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 045

Patient Reported Outcomes in Pediatric Vasculitis

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 078

Periodic Fever Syndrome and Myelodysplastic Syndrome: Possible Connections Between Two Disorders

Posters: Genetics and Pathogenesis I

6:00PM-7:00PM: Abstract Number: 081

Predicting Extension in Juvenile Idiopathic Arthritis

Posters: Genetics and Pathogenesis I

6:00PM-7:00PM: Abstract Number: 050

Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 042

Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 088

Quality Improvement Cycles to Actualize Distribution of the Adolescent Assessment of Preparation for Transition (ADAPT) Survey

Posters: Quality, Health Services, and Education I

6:00PM-7:00PM: Abstract Number: 065

Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA

Posters: Clinical and Therapeutic I

6:00PM-7:00PM: Abstract Number: 084

Rheum to Improve: Patient-reported Transition Readiness in a Large Pediatric Rheumatology Clinic

Posters: Quality, Health Services, and Education I

6:00PM-7:00PM: Abstract Number: 083

Running out of Rheum: Where Are the Pediatric Rheumatology Faculty?

Posters: Quality, Health Services, and Education I

6:00PM-7:00PM: Abstract Number: 086

Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center

Posters: Quality, Health Services, and Education I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].